Index of artpub/2021/270187/

Mareque, M
Cost-effectiveness analysis of gemtuzumab ozogamicin for first-line treatment of patients with cd-33 positive acute myeloid leukaemia in spain
2021
https://ddd.uab.cat/record/270187